Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15587840 | 0.90 | MAP3K12 (0.43) | BRD4HTR2A | |
| SCHEMBL25719734 | 0.90 | HTR2C (0.44) | HTR2CBRD4ATAD2HTR1ASLC6A2 | |
| SCHEMBL1740414 | 0.86 | HRH3 (0.38) | HTR2CBRD4ATAD2HTR3AHTR2A | |
| SCHEMBL28063327 | 0.80 | HRH3 (0.42) | HTR3A | |
| SCHEMBL29940378 | 0.80 | MAP4K4 (0.41) | — | |
| SCHEMBL11996694 | 0.80 | MAP4K4 (0.41) | — | |
| SCHEMBL2636703 | 0.80 | IDO1 (0.39) | HTR2CHTR2ASLC6A2SLC6A4 | |
| SCHEMBL2637316 | 0.79 | TLR9 (0.39) | HTR2CHTR3AHTR2A | |
| SCHEMBL20577260 | 0.79 | TLR9 (0.39) | HTR2CHTR3AHTR2A | |
| SCHEMBL21573257 | 0.77 | MAP4K4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163012-B2 | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2438043-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2010141424-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | HTR2C 4035/4885BRD4 3574/4885ATAD2 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.